SDS Biotech K.K. revised consolidated and non-consolidated earnings guidance for the year ended December 31, 2014. For the year, on consolidated basis, the company forecasts net sales of ¥15,740 million, operating income of ¥1,565 million, ordinary income of ¥1,386 million, net income of ¥813 million or ¥103.90 per share compared to previous guidance for net sales of ¥14,866 million, operating income of ¥1,352 million, ordinary income of ¥1,179 million, net income of ¥684 million or ¥87.35 per share.

For the year, on non-consolidated basis, the company forecasts net sales of ¥11,700 million, ordinary income of ¥1,249 million, net income of ¥831 million or ¥106.15 per share compared to previous guidance for net sales of ¥11,455 million, ordinary income of ¥1,054 million, net income of ¥671 million or ¥85.68 per share.